Simmons R M, Jones D J
Department of Anesthesiology, University of Texas Health Science Center, San Antonio 78284.
Brain Res. 1988 Apr 5;445(2):338-49. doi: 10.1016/0006-8993(88)91196-1.
alpha-Adrenoceptors in spinal cord appear to play a role in a number of physiologic processes including the control of blood pressure, pain and motor function. In order to evaluate more clearly these potential roles, the characteristics of binding of [3H]prazosin ([3H]PRZ) to spinal alpha 1 adrenoceptors and [3H]p-aminoclonidine ([3H]PAC) to spinal alpha 2 adrenoceptors were determined. Binding of each ligand to their respective adrenoceptors was saturable and Scatchard analysis revealed binding of each to a single class of adrenoceptors with characteristics of [3H]PRZ binding of Bmax = 78 fmol/mg protein and Kd = 0.75 nM and [3H]PAC binding Bmax = 70 fmol/mg protein and Kd = 1.39 nM. Whereas [3H]PRZ specific binding (Bmax) was unaltered by guanine nucleotides. [3H]PAC binding was increased with addition of 10 microM guanosine triphosphate (GTP) (P less than 0.05) and decreased with either 50 microM GTP or guanyl-5'-yl-imidodiphosphate [Gpp(NH)p] (P less than 0.01). Competition for specific [3H]PRZ and [3H]PAC binding by various alpha 1 and alpha 2 adrenoceptor agonists and antagonists of known pharmacologic activity revealed that [3H]PRZ defines alpha 1 adrenoceptors (Ki = 2.1 nM for prazosin vs 4300 nM for yohimbine) and [3H]PAC defines alpha 2 adrenoceptors (Ki = 1.06 nM for yohimbine vs 15480 nM for prazosin). Regional spinal cord studies demonstrated that dorsal spinal cord in the lumbar region contains the highest density of both [3H]PRZ (Bmax = 93 +/- 14 fmol/mg protein) and [3H]PAC (Bmax = 101 +/- 6 fmol/mg protein) binding. In contrast, lowest binding was evident in thoracic cord with equal levels in both dorsal and ventral regions (Bmax = 44-48 fmol/mg protein). The regional distribution of both alpha 1 and alpha 2 adrenoceptors in spinal cord compares to the localization previously classified functionally utilizing various pharmacological agonists and antagonists at norepinephrine receptors.
脊髓中的α-肾上腺素能受体似乎在包括血压控制、疼痛和运动功能调节在内的多种生理过程中发挥作用。为了更清楚地评估这些潜在作用,测定了[3H]哌唑嗪([3H]PRZ)与脊髓α1肾上腺素能受体以及[3H]对氨基可乐定([3H]PAC)与脊髓α2肾上腺素能受体的结合特性。每种配体与其各自肾上腺素能受体的结合是可饱和的,Scatchard分析显示每种配体与单一类别的肾上腺素能受体结合,[3H]PRZ结合的特性为Bmax = 78 fmol/mg蛋白质,Kd = 0.75 nM;[3H]PAC结合的特性为Bmax = 70 fmol/mg蛋白质,Kd = 1.39 nM。虽然[3H]PRZ特异性结合(Bmax)不受鸟嘌呤核苷酸影响,但加入10μM鸟苷三磷酸(GTP)可使[3H]PAC结合增加(P<0.05),而加入50μM GTP或鸟苷-5'-亚基-亚氨基二磷酸[Gpp(NH)p]则使其结合减少(P<0.01)。多种已知药理活性的α1和α2肾上腺素能受体激动剂和拮抗剂对[3H]PRZ和[3H]PAC特异性结合的竞争显示,[3H]PRZ界定α1肾上腺素能受体(哌唑嗪的Ki = 2.1 nM,育亨宾的Ki = 4300 nM),[3H]PAC界定α2肾上腺素能受体(育亨宾的Ki = 1.06 nM,哌唑嗪的Ki = 15480 nM)。脊髓区域研究表明,腰段脊髓背侧含有最高密度的[3H]PRZ(Bmax = 93±14 fmol/mg蛋白质)和[3H]PAC(Bmax = 101±6 fmol/mg蛋白质)结合。相比之下,胸段脊髓结合最低,背侧和腹侧区域水平相当(Bmax = 44 - 48 fmol/mg蛋白质)。脊髓中α1和α2肾上腺素能受体的区域分布与先前利用去甲肾上腺素受体的各种药理激动剂和拮抗剂进行功能分类的定位情况相符。